Transformational deals that shaped the Biotech industry in 2015 #BIO-Europe 2015

04/11/2015 - 3 minutes

The Biotech industry relies a lot on partnering and deals. And 2015 has already been an active year.

This was the theme of the second keynote conference from BIO-Europe 2015. It gathered four high-level speakers:

speakers_deal_2015_bio-europe

The roundtable started with a summary of each companies’ activity in deals. Everyone has been busy, but Celgene seemed to be especially active in the first half of the year. As Golumbeski pointed out: it made a major immuno-oncology (PD-L1) deal with AstraZeneca, signed a $1 billion dollars upfront deal with CAR-T company Juno Therapeutics and bought Receptos for $7.2Bn.

A good starting point for the discussion, which started around the many IPOs which occurred since 2014. The moderator asked:

How does that impact your ‘deal activity’?

Golumbeski answered first: this provides an additional options for smaller Biotechs in addition to partnering. Also, the high valuation of Biotechs protects them from bigger Biotechs/Pharma willing to acquire the assets.

Gaal from Almirall was on the same line.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

Support Us

Become a Member